Y Intercept Hong Kong Ltd Has $249,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Y Intercept Hong Kong Ltd lowered its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 47.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,950 shares of the company’s stock after selling 7,966 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its position in shares of Akero Therapeutics by 5.0% during the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after buying an additional 1,000 shares during the last quarter. Rhumbline Advisers boosted its holdings in Akero Therapeutics by 1.3% during the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after acquiring an additional 1,310 shares during the last quarter. abrdn plc boosted its holdings in Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after acquiring an additional 146,424 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Akero Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock worth $412,000 after acquiring an additional 1,446 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AKRO shares. Canaccord Genuity Group upped their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Morgan Stanley boosted their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $76.29.

Akero Therapeutics Trading Down 2.2 %

Shares of AKRO opened at $44.53 on Wednesday. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The business has a 50-day moving average of $39.59 and a 200 day moving average of $32.92. The firm has a market cap of $3.11 billion, a P/E ratio of -11.87 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Insiders Place Their Bets

In other Akero Therapeutics news, CEO Andrew Cheng sold 7,855 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $241,855.45. Following the sale, the chief executive officer now directly owns 597,562 shares in the company, valued at $18,398,933.98. This represents a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Catriona Yale sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00. Following the transaction, the insider now owns 95,648 shares of the company’s stock, valued at $4,769,965.76. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,992 shares of company stock worth $8,509,863 over the last 90 days. Corporate insiders own 7.94% of the company’s stock.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.